

National consensus on *Helicobacter pylori* infection: the next-day challenge

Apostolis Papaefthymiou^{a,b,c},
Michael Doulberis^{b,c,d}, Stergios A. Polyzos^b,
Jannis Kountouras^c

401 General Military Hospital of Athens, Greece;
Aristotle University of Thessaloniki, Macedonia,
Greece; Ippokration Hospital, Aristotle University of
Thessaloniki, Macedonia, Greece; University of Zurich,
Switzerland

The Hellenic Society of Gastroenterology [1] recently published the National consensus on *Helicobacter pylori* (*H. pylori*) infection, following the necessity of a uniform approach to yield optimal eradication rates. As implied by the recent Maastricht V/Florence consensus [2], an “add-on” strategy regarding antibiotics was adapted to overleap the increasing antibiotic resistance, combined with the absence of bismuth-containing drugs, thus perpetuating a “vicious circle” and emerging novel approaches in treatment models with a targeted pathophysiological perspective. Importantly, parameters connected with the multidrug resistance include the formation of *H. pylori*-related biofilms, suggesting the introduction of novel anti-biofilm therapeutic approaches using anti-biofilm agents [3].

A unanimous suggestion (Statement 10) proposed that *H. pylori* culture or molecular techniques should be conducted to evaluate the antimicrobial susceptibility. Nevertheless, those methods are characterized by limited availability in most regions. On the other hand, recent data imply a potential benefit of vitamin D (vitD) for *H. pylori* infection treatment, related to the vitD-receptor's (VDR) antimicrobial role [4-6]. VDR, stimulated by the active *H. pylori* infection, induces human β -defensins, which in high concentrations suppress *H. pylori* biofilm activity [3]; subtle or strong activation of VDR, due to vitD absence or adequacy, could contribute or not to *H. pylori* acclimatization, morbidity, resistance, and survival [3]. Additionally, vitD seems to act directly as an antibacterial agent through stimulation of defensins and cathelicidins, and vitD upregulated protein 1 (VDP1) possesses an *H. pylori*-specific antimicrobial ability, indicating a promising therapeutic potential [7,8]. Moreover, studies in mouse models revealed a protective role of a VDP1 against *H. pylori*-related gastric cancer [9]. Clinical studies concluded that vitD had a protective role against *H. pylori* infection and suggested its deficiency as a distinct risk factor in the failure of eradication treatment, while a recent meta-analysis concluded that vitD supplementation could change the effectiveness of eradication regimens [10]. Therefore, a National multicenter study has recently been inaugurated to elucidate the

relationship between vitD and *H. pylori* infection and the potential beneficial effect of vitD supplementation during eradication treatment.

References

1. Georgopoulos SD, Michopoulos S, Rokkas T, et al. Hellenic consensus on *Helicobacter pylori* infection. *Ann Gastroenterol* 2020;**33**:105-124.
2. Malfertheiner P, Megraud F, O'Morain CA, et al; European Helicobacter and Microbiota Study Group and Consensus panel. Management of *Helicobacter pylori* infection-the Maastricht V/Florence Consensus Report. *Gut* 2017;**66**:6-30.
3. Kazakos EI, Dorrell N, Polyzos SA, Deretzi G, Kountouras J. Comment on “Effect of biofilm formation by clinical isolates of *Helicobacter pylori* on the efflux-mediated resistance to commonly used antibiotics”. *World J Gastroenterol* 2017;**23**:6194-6196.
4. Wanibuchi K, Hosoda K, Ihara M, et al. Indene compounds synthetically derived from vitamin D have selective antibacterial action on *Helicobacter pylori*. *Lipids* 2018;**53**:393-401.
5. Lu C, Yang J, Yu W, et al. Association between 25(OH)D level, ultraviolet exposure, geographical location, and inflammatory bowel disease activity: a systematic review and meta-analysis. *PLoS One* 2015;**10**:e0132036.
6. Guo L, Chen W, Zhu H, et al. *Helicobacter pylori* induces increased expression of the vitamin d receptor in immune responses. *Helicobacter* 2014;**19**:37-47.
7. Wang TT, Nestel FP, Bourdeau V, et al. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. *J Immunol* 2004;**173**:2909-2912.
8. Ramanathan B, Davis EG, Ross CR, Blecha F. Cathelicidins: microbicidal activity, mechanisms of action, and roles in innate immunity. *Microbes Infect* 2002;**4**:361-372.
9. Kwon HJ, Won YS, Nam KT, et al. Vitamin D₃ upregulated protein 1 deficiency promotes N-methyl-N-nitrosourea and *Helicobacter pylori*-induced gastric carcinogenesis in mice. *Gut* 2012;**61**:53-63.
10. Yang L, He X, Li L, Lu C. Effect of vitamin D on *Helicobacter pylori* infection and eradication: a meta-analysis. *Helicobacter* 2019;**24**:e12655.

^aDepartment of Gastroenterology, 401 General Military Hospital of Athens, Greece (Apostolis Papaefthymiou); ^bFirst Laboratory of Pharmacology, School of Medicine, Aristotle University of Thessaloniki, Macedonia, Greece (Apostolis Papaefthymiou, Michael Doulberis, Stergios A. Polyzos); ^cDepartment of Internal Medicine, Second Medical Clinic, Ippokration Hospital, Aristotle University of Thessaloniki, Macedonia, Greece (Apostolis Papaefthymiou, Michael Doulberis, Jannis Kountouras); ^dDepartment of Gastroenterology and Hepatology, University of Zurich, Switzerland (Michael Doulberis)

Conflict of Interest: None

Correspondence to: Jannis Kountouras, Professor of Gastroenterology, Department of Internal Medicine, Second Medical Clinic, Ippokration Hospital, Aristotle University of Thessaloniki, Thessaloniki 54642, Macedonia, Greece, e-mail: jannis@auth.gr

Received 20 January 2020; accepted 5 February 2020;
published online 27 March 2020

DOI: <https://doi.org/10.20524/aog.2020.0469>

Authors' reply

**Sotirios D. Georgopoulos^a,
Pericles Apostolopoulos^b,
Spyridon Michopoulos^c, Theodore Rokkas^d**

Athens Medical, P. Faliron Hospital; NIMTS Hospital, Athens; Alexandra Hospital, Athens; Henry Dynant Hospital, Athens, Greece

We read with great interest the letter by Papaefthymiou *et al* [1] concerning the Greek National Consensus on *Helicobacter pylori* (*H. pylori*) infection [2]. We certainly agree with the authors that over the past years in order to overcome the fast-growing antibiotic resistance of *H. pylori* infection worldwide, an “add-on” strategy has been adapted, and that this is more obvious in countries like Greece, where bismuth salts are not commercially available. Thus, novel *H. pylori* eradication regimens, with a more targeted pathophysiological approach, are under evaluation and we are awaiting with great interest the results of the ongoing clinical trials.

Eradication of *H. pylori* infection has traditionally relied on empiric therapeutic regimens, since the need for endoscopy and the limited availability of culture, in most countries including Greece, have rendered the susceptibility-guided treatment option impractical or even unfeasible. Moreover, a recent randomized study showed that susceptibility-guided therapy in a high-resistance area was equally effective as a local empirical regimen [3], while another randomized study failed to reveal superiority of genotypic resistance-guided therapy over a properly designed empirical treatment for eradication of refractory *H. pylori* infection [4]. For these reasons, the Greek consensus has stated (Statement 26) that culture and antimicrobial susceptibility testing is not recommended before first-line therapy, and that susceptibility-guided therapy should be provided as a rescue treatment, especially after second-line treatment has failed.

On the other hand, the effect of vitamin D (vitD) on *H. pylori* infection and eradication rates has been widely investigated recently [5]. VitD, apart from its well-known role in calcium and phosphorus metabolism, has been proven to be potent immune modulator of the adaptive immune system, stimulating the innate immune response upon infection [6]. Based on these data, several clinical studies have illustrated that vitD analogs may have anti-*H. pylori* antimicrobial effects. Cytological research has also found that vitD₃ decomposition product 1 can lyse *H. pylori* bacterial cells by inducing the collapse of the cell membrane [7]. However, the correlation with vitD has not been fully clarified and studies of the impact of serum vitD levels on *H. pylori* eradication were mostly observational or retrospective and of small sample size [8-10].

Therefore, well-designed randomized controlled prospective studies with a large sample size are needed. We were delighted to hear that a national multicenter study on the relationship between vitD and *H. pylori* was recently launched and we are awaiting the results.

References

1. Papaefthymiou A, Doulberis M, Polyzos SA, Kountouras J. National consensus on *Helicobacter pylori* infection: the next-day challenge. *Ann Gastroenterol* 2020;**33**:324.
2. Georgopoulos SD, Michopoulos S, Rokkas T, et al. Hellenic consensus on *Helicobacter pylori* infection. *Ann Gastroenterol* 2020;**33**:105-124.
3. Chen Q, Long X, Ji Y, et al. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line *Helicobacter pylori* treatment. *Aliment Pharmacol Ther* 2019;**49**:1385-1394.
4. Liou JM, Chen PY, Luo JC, et al; Taiwan Gastrointestinal Disease and Helicobacter Consortium. Efficacies of genotypic resistance- guided vs empirical therapy for refractory *Helicobacter pylori* infection. *Gastroenterology* 2018;**155**:1109-1119.
5. Han C, Ni Z, Yuan T, et al. Influence of serum vitamin D level on *Helicobacter pylori* eradication: a multi-center, observational, prospective and cohort study. *J Dig Dis* 2019;**20**:421-426.
6. Baeke F, Takiishi T, Korf H, Gysemans C, Mathieu C. Vitamin D: modulator of the immune system. *Curr Opin Pharmacol* 2010;**10**:482-496.
7. Wanibuchi K, Hosoda K, Ihara M, et al. Indene compounds synthetically derived from vitamin D have selective antibacterial action on *Helicobacter pylori*. *Lipids* 2018;**53**:393-401.
8. Yildirim O, Yildirim T, Seckin Y, Osanmaz P, Bilgic Y, Mete R. The influence of vitamin D deficiency on eradication rates of *Helicobacter pylori*. *Adv Clin Exp Med* 2017;**26**:1377-1381.
9. Huang B, Yan S, Chen C, Ye S. Effect of 25-hydroxyvitamin D on *Helicobacter pylori* eradication in patients with type 2 diabetes. *Wien Klin Wochenschr* 2019;**131**:75-80.
10. El Shahawy MS, Hemida MH, El Metwaly I, Shady ZM. The effect of vitamin D deficiency on eradication rates of *Helicobacter pylori* infection. *JGH Open* 2018; **2**:270-275.

^aGI Department Athens Medical, P. Faliron Hospital, P. Faliron, Greece;

^bGI Department NIMTS Hospital, Athens, Greece; ^cGI Department Alexandra Hospital, Athens, Greece; ^dGI Department Henry Dynant Hospital, Athens, Greece

Conflict of Interest: None

Correspondence to: Sotirios D. Georgopoulos, MD, FEBGH, AGAF, Director, GI Department, Athens Medical, P. Faliron Hospital, 144 Kountouriotou Str., 18535 Piraeus, Greece, e-mail: georgpap@ath.forthnet.gr

Received 3 February 2020; accepted 5 February 2020; published online 27 March 2020

DOI: <https://doi.org/10.20524/aog.2020.0472>